Salvage radiotherapy vs hormone therapy for prostate-specific antigen failure after radical prostatectomy: A randomized, multicentre, open-label, phase 3 trial (JCOG0401)

European Urology Dec 26, 2019

Yokomizo A, Wakabayashi M, Satoh T, et al. - In this multicentre, randomized, open-label, phase 3 trial, 210 individuals (105 in each arm) with localized prostate cancer whose prostate-specific antigen (PSA) concentrations had declined to < 0.1 ng/ml following radical prostatectomy (RP), and then rose to 0.4–1.0 ng/ml, were randomized to the salvage hormone therapy group (SHT) or the salvage radiation therapy (SRT) ± SHT group in order to ascertain whether radiotherapy ± hormone therapy was better than hormone therapy alone in such individuals. It was discovered that initial SRT prolonged time to treatment failure of bicalutamide in individuals with post-RP PSA failure, designating that SRT ± SHT is more advantageous compared with SHT alone.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen